Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"Phase: Phase 3"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?lookfor=%22Standard+of+Care%22&type=Subject&filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+3%22
/vufind/Search/Results?lookfor=%22Standard+of+Care%22&type=Subject&filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+3%22
Search /vufind/Search2/Results?lookfor=%22Standard+of+Care%22&type=Subject&filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+3%22
PubPharm (105)
1
89Zirconium-labelled girentuximab (89Zr-TLX250) is a new diagnostic imaging agent which has a radionuclide (zirconium-89) linked with a drug known as girentuximab. The drug is known to be taken up by clear cell renal cell carcinoma. This product would be administered and then a scan of the body made by a PET/CT machine. This study is to determine the ability of the administered zirconium-89 girentuximab to correctly identify the nature of the known or suspected cancer within your kidney. : A confirmatory, prospective, open-label, multi-centre phase 3 study to evaluate diagnostic performance of 89Zirconium-labelled girentuximab(89Zr-TLX250) to non-invasively detect clear cell renal cell carcinoma (ccRCC) by positron emission tomography/CT (PET/CT) imaging in patients with indeterminate renal masses (ZIRCON study) - 89Zr-TLX250 for PET/CT imaging of ccRCC
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
2
89Zirconium-labelled girentuximab (89Zr-TLX250) is a new diagnostic imaging agent which has a radionuclide (zirconium-89) linked with a drug known as girentuximab. The drug is known to be taken up by clear cell renal cell carcinoma. This product would be administered and then a scan of the body made by a PET/CT machine. This study is to determine the ability of the administered zirconium-89 girentuximab to correctly identify the nature of the known or suspected cancer within your kidney. : A confirmatory, prospective, open-label, multi-centre phase 3 study to evaluate diagnostic performance of 89Zirconium-labelled girentuximab(89Zr-TLX250) to non-invasively detect clear cell renal cell carcinoma (ccRCC) by positron emission tomography/CT (PET/CT) imaging in patients with indeterminate renal masses (ZIRCON study) - 89Zr-TLX250 for PET/CT imaging of ccRCC
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
3
A comparison of standard versus robotic total knee replacement : Robotic Arthroplasty: a Clinical and cost Effectiveness Randomised controlled trial (RACER)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
4
A comparison of standard versus robotic total knee replacement : Robotic Arthroplasty: a Clinical and cost Effectiveness Randomised controlled trial (RACER)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
5
A study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) : A 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy - OCEAN
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
6
A study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) : A 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy - OCEAN
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
7
Open-label, Dose escalation, followed by Double-blind, Randomized, Two-dose, Parallel Group, Multi-center Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with Mycosis Fungoides type CTCL (stage IB-IVB) who are Refractory or Intolerant to Targretin® (bexarotene) and one other Standard Therapy - HuMax-CD4 in Refractory Mycosis Fungoides : Open-label, Dose escalation, followed by Double-blind, Randomized, Two-dose, Parallel Group, Multi-center Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with Mycosis Fungoides type CTCL (stage IB-IVB) who are Refractory or Intolerant to Targretin® (bexarotene) and one other Standard Therapy - HuMax-CD4 in Refractory Mycosis Fungoides
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
8
Study to test effectiveness and safety of a new drug, Ibrexafungerp in patients with fungal diseases who do not easily respond to, or who are intolerant to, the current treatment for their disease. : Open-Label Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients with Fungal Diseases that are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
9
A study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) : A 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy - OCEAN
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
10
Open-label, Dose escalation, followed by Double-blind, Randomized, Two-dose, Parallel Group, Multi-center Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with Mycosis Fungoides type CTCL (stage IB-IVB) who are Refractory or Intolerant to Targretin® (bexarotene) and one other Standard Therapy - HuMax-CD4 in Refractory Mycosis Fungoides : Open-label, Dose escalation, followed by Double-blind, Randomized, Two-dose, Parallel Group, Multi-center Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with Mycosis Fungoides type CTCL (stage IB-IVB) who are Refractory or Intolerant to Targretin® (bexarotene) and one other Standard Therapy - HuMax-CD4 in Refractory Mycosis Fungoides
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[11]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Thema: Phase: Phase 3
Medienart
105
Aufsätze
105
E-Artikel
105
E-Ressourcen
Zeitschriftentitel
104
WHO International Clinical Trials Registry Plat...
1
ClinicalTrials.gov
Thema
105
610
Phase: Phase 3
105
Study Type: Interventional
60
Recruitment Status: Not yet recruiting
32
Recruitment Status: Authorised-recruitment may ...
14
Medical Condition: The study objective is to ev...
6
Medical Condition: Adjuvant treatment for women...
6
Medical Condition: First-line treatment of exte...
6
Medical Condition: First-line treatment of exte...
6
Medical Condition: Patients > 18 years of age w...
6
Medical Condition: Relapsing or refractory Eosi...
4
Medical Condition: AdV infection in pediatric a...
4
Medical Condition: Patients with an indetermina...
4
Medical Condition: The main purpose of this tri...
4
Medical Condition: The study objective is to ev...
2
Medical Condition: About one-third of patient w...
2
Medical Condition: About one-third of patient w...
2
Medical Condition: About one-third of patient w...
2
Medical Condition: About one-third of patients ...
2
Medical Condition: Adjuvant treatment for women...
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
71
2020-
34
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
103
Englisch
2
Spanisch
Haven't found what you're looking for?
Wird geladen...